Calreticulin is highly expressed in pancreatic cancer stem-like cells

详细信息    查看全文

• 作者：Satoshi Matsukuma ; Kiyoshi Yoshimura ; Tomio Ueno ; Atsunori Oga ; Moeko Inoue ; Yusaku Watanabe ; Atsuo Kuramasu ; Masanori Fuse ; Ryouichi Tsunedomi ; Satoshi Nagaoka ; Hidetoshi Eguchi ; Hiroto Matsui ; Yoshitaro Shindo ; Noriko Maeda ; Yoshihiro Tokuhisa ; Reo Kawano ; Tomoko Furuya-Kondo ; Hiroshi Itoh ; Shigefumi Yoshino ; Shoichi Hazama ; Masaaki Oka and Hiroaki Nagano
• 刊名：Cancer Science
• 出版年：2016
• 出版时间：November 2016
• 年：2016
• 卷：107
• 期：11
• 页码：1599-1609
• 全文大小：3133K
• ISSN：1349-7006

文摘

Cancer stem-like cells (CSLCs) in solid tumors are thought to be resistant to conventional chemotherapy or molecular targeting therapy and to contribute to cancer recurrence and metastasis. In this study, we aimed to identify a biomarker of pancreatic CSLCs (P-CSLCs). A P-CSLC-enriched population was generated from pancreatic cancer cell lines using our previously reported method and its protein expression profile was compared with that of parental cells by 2-D electrophoresis and tandem mass spectrometry. The results indicated that a chaperone protein calreticulin (CRT) was significantly upregulated in P-CSLCs compared to parental cells. Flow cytometry analysis indicated that CRT was mostly localized to the surface of P-CSLCs and did not correlate with the levels of CD44v9, another P-CSLC biomarker. Furthermore, the side population in the CRT^high/CD44v9^low population was much higher than that in the CRT^low/CD44v9^high population. Calreticulin expression was also assessed by immunohistochemistry in pancreatic cancer tissues (n = 80) obtained after radical resection and was found to be associated with patients' clinicopathological features and disease outcomes in the Cox proportional hazard regression model. Multivariate analysis identified CRT as an independent prognostic factor for pancreatic cancer patients, along with age and postoperative therapy. Our results suggest that CRT can serve as a biomarker of P-CSLCs and a prognostic factor associated with poorer survival of pancreatic cancer patients. This novel biomarker can be considered as a therapeutic target for cancer immunotherapy.